Eighteen relapsed patients with measurable indolent non-Hodgkin lymphoma (NHL) were vaccinated with dendritic cells (DC s) loaded with killed autologous tumor cells. Six patients had objective clinical responses including 3 continuous complete responses (CR s) and 3 partial responses (PR s), with a median follow up of 50.5 months. Eight patients had stable disease, whereas 4 had progressive disease. Clinical responses were significantly associated with a reduction in CD4 +CD25 +FOXP3 + regulatory T cells, an increase in CD3 -CD56 dimCD16 + natural killer (NK) cells, and maturation of lymphocytes to the effector memory stage in either postvaccination peripheral blood or tumor specimen samples. In partial responding patients, vaccination significantly boosted the IFN- γ-producing Tcell response to autologous tumor challenge. In one HLA-Aandz.ast;0201 + patient who achieved CR, IL-4 release by circulating T cells in response to tumor-specific IgHencoded peptides was also documented. Immunohistochemical analysis of tumor biopsies using biotin-conjugated autologous serum samples revealed a tumorrestricted humoral response only in the postvaccination serum from responding patients. Collectively these results demonstrate that vaccination with tumorloaded DCs may induce both T- and B-cell responses and produces clinical benefits in indolent NHL patients with measurable disease. This study is registered with the Istituto Superiore di Sanità: http://www.iss.it with protocol number 7578-PRE 21-801. (Blood. 2009;113:18-27).
ASJC Scopus subject areas
- Cell Biology